Madrigal Pharmaceuticals Inc (MDGL) — Institutional Holders Breakdown (Q2 2026)

MDGL ranks #1460 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

MDGL is a top-conviction position for Paulson & Co. Inc. — at 27.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in MDGL belongs to Baker Bros. Advisors LP, but the position matters far more to Paulson & Co. Inc., who has 27.9% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Ken Griffin has added to its MDGL position for two straight quarters, increasing it by $262.3M to reach $369.5M today.

BlackRock has trimmed its MDGL position for two straight quarters, cutting it by $313.0M while still holding $644.8M.

MDGL is up 5.2% today, and institutions have been net buyers of $3.9B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

MDGL reported a net loss of $325.1M over the trailing twelve months.

• Not yet profitable — net loss of $325.1M over the trailing twelve months
• Revenue grew 149.0% year over year
• Net income declined year over year, from -$281.9M to -$325.1M
• Operating cash flow was negative, using $189.6M in cash
• Current ratio of 4.01x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.09x equity — within a conventional range